Under the terms of this agreement, which has a 10-year term, Biovail will manufacture and supply once-daily extended-release tramadol hydrochloride tablets in dosage strengths of 100mg, 200mg and 300mg to Janssen at contractually determined prices. Janssen affiliates will be responsible for all related promotional costs, as well as all regulatory filings and the management of the regulatory approvals process.
Douglas Squires, interim chairman and CEO of Biovail, said: “This agreement furthers our existing relationship with Ortho-McNeil, an affiliate of Janssen which markets our once-daily tramadol in the US.”